Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Thermo Fisher Scientific Inc.NYSE: TMO
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows in line with its trailing trend
Q3 FY2026 research & development of $348M rose 0.3% year over year, ahead of the -0.7% change in trailing-twelve-month research & development. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.
Context
- Research & development amounted to 3.1% of revenue in FY2025, down 0.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -0.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.4B USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- -0.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.4B | +0.5% |
| FY2024 | 2024-12-31 | 1.39B | +4.0% |
| FY2023 | 2023-12-31 | 1.34B | -9.1% |
| FY2022 | 2022-12-31 | 1.47B | +4.6% |
| FY2021 | 2021-12-31 | 1.41B | — |
Research & Development vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's LTM Sep 2026 research & development of $1.41B is the 2nd highest of the 10 companies compared; the peer median is $261.1M.
- Its year-over-year change of -0.7% is the 7th highest of 10, against a peer median of +5.2%.
- Research & development amounts to 3.0% of revenue for TMO, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jul 2026 | $321.75M | +71.7% | +3.5% | 6.9% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $208.01M | +7.9% | +4.0% | 5.0% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| Peer median (excluding TMO) | $261.1M | +5.2% | +0.8% | 7.4% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B |
| Cost of Revenue | 19.58B | 25.9B | 25.66B | 25.15B | 26.32B |
| Gross Profit | 19.63B | 19.01B | 17.19B | 17.73B | 18.24B |
| Gross Margin | 50.1% | 42.3% | 40.1% | 41.3% | 40.9% |
| Research & Development | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B |
| Selling, General & Admin | 7.91B | 9.02B | 8.41B | 8.68B | 8.73B |
| Operating Expenses | 9.32B | 10.49B | 9.75B | 10.07B | 10.13B |
| Depreciation & Amortization | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| EBITDA | 11.97B | 11.94B | 11.2B | 11.8B | 11.47B |
| EBITDA Margin | 30.5% | 26.6% | 26.1% | 27.5% | 25.7% |
| Operating Income | 10.32B | 8.53B | 7.45B | 7.66B | 8.11B |
| Operating Margin | 26.3% | 19.0% | 17.4% | 17.9% | 18.2% |
| Interest Income | 43M | 272M | 879M | 1.08B | 993M |
| Interest Expense | 536M | 726M | 1.49B | 1.65B | 1.42B |
| Other Income / Expenses | (1.48B) | (862M) | (1.21B) | (667M) | (842M) |
| Income Before Tax | 8.84B | 7.66B | 6.24B | 7B | 7.27B |
| Pre-Tax Margin | 22.5% | 17.1% | 14.6% | 16.3% | 16.3% |
| Income Tax Expense | 1.11B | 703M | 284M | 657M | 547M |
| Net Income | 7.73B | 6.95B | 6B | 6.34B | 6.74B |
| Net Margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% |
| EPS (Basic) | 19.61 | 17.73 | 15.53 | 16.58 | 17.77 |
| EPS (Diluted) | 19.46 | 17.64 | 15.45 | 16.53 | 17.74 |
| Weighted Avg Shares | 394M | 392M | 386M | 382M | 376M |
| Weighted Avg Shares (Diluted) | 397M | 394M | 388M | 383M | 377M |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.